-
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting -
Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting
Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting -
Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease -
Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients -
AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis
AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis -
Investors are pouring hundreds of millions into startups working to treat hearing loss.
Investors are pouring hundreds of millions into startups working to treat hearing loss. -
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery -
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
-
Wall Street warms to Bicycle history makers
Wall Street warms to Bicycle history makers -
Biotechs Race to Develop Stem Cell Treatments for Diabetes
Biotechs Race to Develop Stem Cell Treatments for Diabetes -
Disarm Therapeutics Announces Science Publications Elucidating Structure and Function of SARM1
Disarm Therapeutics Announces Science Publications Elucidating Structure and Function of SARM1 -
Gene-Therapy Startup Neurogene Adds Fuel With $68 Million Round
Gene-Therapy Startup Neurogene Adds Fuel With $68 Million Round -
Casma Therapeutics Named a 2019 “Fierce 15” Biotech Company
Casma Therapeutics Named a 2019 “Fierce 15” Biotech Company -
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting -
Sigilon coming on strong
Sigilon coming on strong -
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens -
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field -
‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different
‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different -
New Cambridge biotech Korro aims to develop a reversible form of gene editing
New Cambridge biotech Korro aims to develop a reversible form of gene editing -
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting
-
Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting
Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting
-
Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
-
Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
-
AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis
AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis
-
Investors are pouring hundreds of millions into startups working to treat hearing loss.
Investors are pouring hundreds of millions into startups working to treat hearing loss.
-
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
-
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
-
Wall Street warms to Bicycle history makers
Wall Street warms to Bicycle history makers
-
Biotechs Race to Develop Stem Cell Treatments for Diabetes
Biotechs Race to Develop Stem Cell Treatments for Diabetes
-
Disarm Therapeutics Announces Science Publications Elucidating Structure and Function of SARM1
Disarm Therapeutics Announces Science Publications Elucidating Structure and Function of SARM1
-
Gene-Therapy Startup Neurogene Adds Fuel With $68 Million Round
Gene-Therapy Startup Neurogene Adds Fuel With $68 Million Round
-
Casma Therapeutics Named a 2019 “Fierce 15” Biotech Company
Casma Therapeutics Named a 2019 “Fierce 15” Biotech Company
-
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
-
Sigilon coming on strong
Sigilon coming on strong
-
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
-
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field
-
‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different
‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different
-
New Cambridge biotech Korro aims to develop a reversible form of gene editing
New Cambridge biotech Korro aims to develop a reversible form of gene editing
-
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting
-
Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting
Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting
-
Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
-
Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
-
AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis
AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis
-
Investors are pouring hundreds of millions into startups working to treat hearing loss.
Investors are pouring hundreds of millions into startups working to treat hearing loss.
-
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
-
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
-
Wall Street warms to Bicycle history makers
Wall Street warms to Bicycle history makers
-
Biotechs Race to Develop Stem Cell Treatments for Diabetes
Biotechs Race to Develop Stem Cell Treatments for Diabetes
-
Disarm Therapeutics Announces Science Publications Elucidating Structure and Function of SARM1
Disarm Therapeutics Announces Science Publications Elucidating Structure and Function of SARM1
-
Gene-Therapy Startup Neurogene Adds Fuel With $68 Million Round
Gene-Therapy Startup Neurogene Adds Fuel With $68 Million Round
-
Casma Therapeutics Named a 2019 “Fierce 15” Biotech Company
Casma Therapeutics Named a 2019 “Fierce 15” Biotech Company
-
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
-
Sigilon coming on strong
Sigilon coming on strong
-
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
-
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field
-
‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different
‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different
-
New Cambridge biotech Korro aims to develop a reversible form of gene editing
New Cambridge biotech Korro aims to develop a reversible form of gene editing